Currently, selectively targeting BCR-ABL kinase is the standard of care for CML using tyrosine kinase inhibitors (TKIs) including imatinib, dasatinib, and nilotinib, and has manifested clinical benefits in improving patients’ survival3,4. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.